IL33-ST2 axis is a predictive biomarker for anti-PD1 therapeutic efficacy in advanced gastric cancer
These data suggest high IL33/ST2 levels are significant poor prognostic factors for nivolumab therapy for advanced GC. The IL33/ST2 axis may be useful as a biomarker for predicting and pre-selecting possible responders/nonresponders to anti-PD1/PDL1 therapy for GC, and hopefully as a druggable target for developing new drugs for treating GC. The IL33/ST2-targeting strategy will contribute to improving clinical outcomes in the treatment of GC.
Authors
- Hirokazu Shoji (ORCID: https://orcid.org/0000-0002-8922-5227)
- Hiroshi Imazeki
- Hitoshi Ichikawa (ORCID: https://orcid.org/0000-0003-0142-2240)
- Kei Muro
- Rika Kizawa (ORCID: https://orcid.org/0000-0003-1275-9228)
- Kengo Nagashima (ORCID: https://orcid.org/0000-0003-4529-9045)
- Naohiro Okano
- Naoki Takahashi (ORCID: https://orcid.org/0000-0002-7946-6078)
- Yukiya Narita (ORCID: https://orcid.org/0000-0002-8018-0077)
- Kai Tsugaru (ORCID: https://orcid.org/0000-0001-7763-7999)
- Yoshiyuki Yamamoto (ORCID: https://orcid.org/0000-0002-2932-5904)
- Takeru Wakatsuki (ORCID: https://orcid.org/0000-0002-1463-3859)
- Takeshi Kawakami (ORCID: https://orcid.org/0000-0001-9385-9516)
- Narikazu Boku
- Yusuke Amanuma
- Chie Kudo‐Saito (ORCID: https://orcid.org/0000-0003-4644-9404)
Institutions
- Kyorin University (JP)
- National Cancer Centre Japan (JP)
- Shizuoka Cancer Center (JP)
- Keio University Hospital (JP)
- University of Tsukuba Hospital (JP)
- Chiba Cancer Center (JP)
- Saitama Cancer Center (JP)
- Aichi Cancer Center (JP)
- The Cancer Institute Hospital (JP)
- National Cancer Center Hospital East (JP)
- Toranomon Hospital (JP)
- National Cancer Research Institute (GB)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1186/s12967-025-07145-3
- Primary Topic
- IL-33, ST2, and ILC Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Ono Pharmaceutical